A necroptosis inhibitor is a drug or chemical compound that blocks a specific type of inflammatory cell death called necroptosis, usually by disabling one of the key proteins in the chain reaction that causes a cell to rupture. The most well-known example, necrostatin-1, works by targeting RIPK1, the first kinase in the signaling cascade. But the field has expanded well beyond that single molecule, with inhibitors now aimed at different points along the pathway and several already being tested in human clinical trials for conditions ranging from neurodegenerative disease to heart attack.
How Necroptosis Kills a Cell
To understand what necroptosis inhibitors block, you need a rough picture of what they’re blocking. Necroptosis is a form of programmed cell death, meaning the cell doesn’t die by accident. It follows a defined sequence of molecular steps. But unlike apoptosis, the quieter and more common form of programmed death where a cell neatly packages itself for recycling, necroptosis ends with the cell’s membrane bursting open and spilling its contents into surrounding tissue. That spill triggers inflammation, which is why necroptosis matters so much in disease.
The process runs through three main proteins, each handing off a signal to the next. First, RIPK1 is activated by external signals such as tumor necrosis factor (TNF), a molecule the immune system uses to flag danger. RIPK1 then recruits and activates RIPK3. Together, these two kinases assemble into a structure called the necrosome, a cytosolic signaling platform that serves as the engine of the process.1PubMed Central. Nuclear RIPK3 and MLKL contribute to cytosolic necrosome formation and necroptosis RIPK3 then phosphorylates the final protein in the chain, MLKL. Once phosphorylated, MLKL changes shape, forms clusters, and moves from the interior of the cell to the plasma membrane, where it punches holes in the membrane and destroys it.2Molecular Cell. Mixed Lineage Kinase Domain-like Protein MLKL Causes Necrotic Membrane Disruption upon Phosphorylation by RIP3 The cell dies, its contents leak out, and an inflammatory response kicks off in the surrounding area.
What normally keeps this from happening in healthy cells is caspase-8, an enzyme that cleaves RIPK1 and shuts the pathway down, diverting the cell toward apoptosis instead. Necroptosis tends to fire when caspase-8 is missing, blocked, or overwhelmed, which happens in various disease states and during certain viral infections.3PubMed Central. Differences of Key Proteins between Apoptosis and Necroptosis
Where Inhibitors Intervene
Because necroptosis is a relay with three main handoff points, inhibitors can target any of the three core proteins. Most drug development has focused on the first two.
RIPK1 inhibitors are the most extensively studied class. Blocking RIPK1 stops the cascade at its origin, before the necrosome assembles and before MLKL ever gets activated. Necrostatin-1, the compound that essentially launched the field, is a RIPK1-targeted small molecule that has been widely used in laboratory experiments to demonstrate the role of necroptosis in disease models.4PubMed Central. Necrostatin-1 and necroptosis inhibition: Pathophysiology and therapeutic implications Since necrostatin-1 was first described, researchers have developed more refined RIPK1 inhibitors that bind to either an allosteric pocket on the kinase (a site away from its active center) or to both the allosteric pocket and the ATP-binding site, improving potency and selectivity.5PubMed. Structure-based development of potent and selective type-II kinase inhibitors of RIPK1
RIPK3 inhibitors target the middle step. In a mouse model of inflammatory bowel disease, a compound called GSK’872 specifically blocked RIPK3 activity and rescued the intestinal damage. Mice that had been losing weight, developing diarrhea, and suffering severe colon inflammation showed significant improvement after treatment, with reduced cell death and lower levels of both phosphorylated RIPK3 and MLKL in their colon tissue.6The Journal of Clinical Investigation. Epithelial Gab1 calibrates RIPK3-dependent necroptosis to prevent intestinal inflammation RIPK3 inhibitors have received less clinical attention than RIPK1 inhibitors so far, partly because RIPK3’s biology is more complicated and partly because early drug candidates had off-target effects.
MLKL, the executioner protein, is also a potential target. Blocking MLKL would stop the final step of membrane destruction. Some research groups are working on this approach, but MLKL-targeted drugs are at an earlier stage than RIPK1 inhibitors. The idea is appealing because MLKL sits at the bottleneck of the pathway. Once MLKL inserts into a cell’s membrane and forms permeation pores, the cell is essentially doomed.7PubMed Central. Switch for the necroptotic permeation pore Catching it before that point could be useful in situations where upstream signaling is hard to block.
Diseases Where Blocking Necroptosis Could Help
The reason necroptosis inhibitors attract so much research interest is that unwanted necroptotic cell death shows up across a surprisingly wide range of diseases. Because necroptosis produces inflammation as a byproduct, any condition where tissue damage and inflammation feed on each other is a plausible target.
In stroke, when blood flow to part of the brain is cut off and then restored, the reperfusion phase causes a wave of cell death that extends well beyond the initial oxygen-starved area. Studies in animal models of ischemic stroke have shown that necrostatin-1 blocks the activation of RIPK1, RIPK3, and MLKL in brain tissue, and also reduces the production of the inflammatory molecule IL-1β.8PubMed Central. Necrostatin-1 Prevents Necroptosis in Brains after Ischemic Stroke via Inhibition of RIPK1-Mediated RIPK3/MLKL Signaling A similar process occurs in the heart during a heart attack: necroptosis inhibitors tested in preclinical models reduced the size of the infarct, lowered inflammation, and helped restore cardiac function.9PubMed Central. Pharmaceutical Therapies for Necroptosis in Myocardial Ischemia-Reperfusion Injury
Neurodegenerative diseases are another major area of interest. Growing evidence links necroptosis to the progressive loss of neurons in conditions like Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and Parkinson’s disease.10PubMed Central. Necroptosis in neurodegenerative diseases: a potential therapeutic target In Parkinson’s disease specifically, researchers used human stem-cell-derived neurons carrying a mutation associated with the disease and found that blocking necroptosis rescued the survival deficit in those cells. The same approach protected dopamine-producing neurons in a mouse model of Parkinson’s.11PubMed Central. Pharmacological Inhibition of Necroptosis Protects from Dopaminergic Neuronal Cell Death in Parkinson’s Disease Models These are preclinical results, not treatments available to patients yet, but they’ve driven several compounds into human trials.
Necroptosis Inhibitors in Human Trials
The leap from lab to clinic is always the hardest part, and necroptosis inhibitors are in the thick of it. Several RIPK1 inhibitors have now been tested in early-phase clinical trials, and the picture is cautiously encouraging with one notable stumble.
GFH312 was tested in a phase I trial in healthy volunteers at single doses up to 500 mg and repeated daily doses up to 200 mg for two weeks. The drug was well tolerated, with no serious adverse events. The most common side effect was headache, reported in about a fifth of participants. The trial confirmed that GFH312 inhibited RIPK1 activity in the body.12PubMed Central. A phase I randomized, double-blinded, placebo-controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects
Eclitasertib, another RIPK1 inhibitor, showed a similarly clean safety profile. At doses of 100 mg and above, the drug achieved over 90% inhibition of RIPK1 phosphorylation in immune cells at 12 hours after a dose. No drug-related serious or severe adverse events were reported, and eating a high-fat meal did not significantly change the drug’s absorption.13PubMed Central. A Randomized Phase I Trial Evaluating Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eclitasertib, a RIPK1 Inhibitor, in Healthy Participants
The cautionary tale belongs to SAR443060 (originally called DNL747), developed for Alzheimer’s and ALS. In early trials, the drug reached the cerebrospinal fluid after oral dosing, confirmed target engagement in blood cells, and was well tolerated during the short treatment periods tested in both healthy volunteers and patients. But development was discontinued because long-term toxicity studies in animals revealed concerning findings. Critically, the researchers noted that these toxic effects appeared to be specific to the compound itself, not to RIPK1 inhibition as a concept, since other RIPK1 inhibitors in development have not triggered similar signals.14PubMed Central. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients That distinction matters because it means the door hasn’t closed on RIPK1 inhibition for brain diseases; scientists just need compounds with better safety margins.
The Complicated Role in Cancer
Cancer is where the story of necroptosis inhibitors gets genuinely messy. In many diseases, necroptosis is the villain, and blocking it seems straightforwardly beneficial. In cancer, necroptosis is playing for both teams.
On one hand, necroptosis can be a powerful cancer-fighting mechanism. When tumor cells die by necroptosis, their contents spill out and alert the immune system, triggering a strong adaptive immune response that can attack the tumor. Some cancer therapies are actually designed to induce necroptosis in tumor cells for this exact reason. On the other hand, the chronic inflammation that necroptosis generates in and around tumors can also promote tumor growth and metastasis. Necroptosis in the tumor microenvironment can even create an immunosuppressive environment that helps the cancer evade the immune system.15PubMed Central. The role of necroptosis in cancer biology and therapy
This means that using necroptosis inhibitors in cancer patients requires extreme care about context. In a cancer where necroptosis is promoting inflammation that feeds tumor growth, an inhibitor could help. In a cancer where the immune system is relying on necroptotic signaling to detect and kill tumor cells, the same inhibitor could make things worse. The field hasn’t sorted this out yet, and it’s one reason why necroptosis-targeting therapies in oncology lag behind those in inflammatory and neurodegenerative diseases.
When Cells Switch Death Pathways
One of the trickiest challenges for necroptosis inhibitors is that cells aren’t limited to a single way of dying. Block one death pathway, and a cell under sufficient stress may simply activate another one. This is not a theoretical concern; it shows up consistently in experiments.
The relationship between apoptosis and necroptosis is the best-studied example. As mentioned earlier, caspase-8 normally cleaves RIPK1 and RIPK3 to suppress necroptosis. Researchers engineered mice with a form of RIPK3 that can’t be cleaved by caspase-8, expecting this might unleash necroptosis. Instead, the mice were viable, meaning the inability to cleave RIPK3 didn’t make necroptosis run rampant. What did change was that these cells became more prone to a different form of inflammatory death: pyroptosis, driven by the NLRP3 inflammasome, with increased secretion of IL-1β.16PubMed Central. RIPK3 cleavage is dispensable for necroptosis inhibition but restricts NLRP3 inflammasome activation The system compensated, but not in a benign way.
The emerging concept of PANoptosis captures this problem more broadly. PANoptosis describes situations where pyroptosis, apoptosis, and necroptosis are all interconnected through shared upstream sensor molecules, and blocking the executioners of one arm of cell death can steer the dying process toward a different arm.17Cell Death & Disease. Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases For drug developers, this means a necroptosis inhibitor alone might not prevent cell death in all settings. It might just change how the cell dies. In some diseases, that shift could be enough to reduce harmful inflammation. In others, it might redirect cells into an equally damaging form of death. The practical implication is that necroptosis inhibitors may end up working best in combination with drugs that also block apoptotic or pyroptotic pathways, though such combination strategies are still in early investigation.
Measuring Necroptosis in Patients
A challenge that doesn’t get as much public attention as drug development but looms large over the field is the difficulty of measuring necroptosis in living patients. In a laboratory dish, you can stain cells, measure phosphorylated MLKL, and image membrane rupture directly. In a person, you’re working with blood samples and indirect readouts.
The core biomarker approach relies on detecting phosphorylated forms of RIPK1, RIPK3, or MLKL in tissue or blood. In the eclitasertib trial, for instance, researchers measured phosphorylated RIPK1 in peripheral blood immune cells to confirm the drug was hitting its target.13PubMed Central. A Randomized Phase I Trial Evaluating Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eclitasertib, a RIPK1 Inhibitor, in Healthy Participants But the gap between “the drug inhibits RIPK1 in blood cells” and “the drug prevents necroptosis in the brain” or “the drug prevents necroptosis in the heart” is wide. Identifying reliable biomarkers for use in diagnosis, monitoring, and drug development remains an increasingly important need in translational necroptosis research.18PubMed Central. Biomarkers for the detection of necroptosis Without good biomarkers, it’s hard to know whether a patient’s disease is actually being driven by necroptosis, making it difficult to select the right patients for clinical trials or to measure whether a drug is working in the tissues that matter.
Viruses That Carry Their Own Necroptosis Inhibitors
Perhaps the most striking evidence that necroptosis inhibition is a viable survival strategy comes not from pharmaceutical labs but from evolution. Several viruses have independently evolved proteins whose entire job is to block necroptosis in host cells.
Cytomegalovirus, herpes simplex virus, and vaccinia virus all produce proteins that compete with the host’s cell-death machinery, preventing programmed death pathways from being initiated.19PubMed. Cell-type dependence of necroptosis pathways triggered by viral infection The logic is straightforward from the virus’s perspective: if the infected cell dies before the virus finishes replicating, the virus loses its factory. By shutting down necroptosis, these viruses keep the cell alive long enough to produce more copies of themselves. The host’s immune system, in turn, uses necroptosis as a defense precisely because it is inflammatory. A necroptotic cell doesn’t just die quietly; it sounds an alarm. The evolutionary arms race between viral necroptosis inhibitors and host necroptotic defenses has been going on far longer than human drug development, and it offers a kind of natural proof-of-concept that interfering with this pathway changes outcomes in real biological systems.
This viral biology also raises a practical question for drug development. If you give a patient a necroptosis inhibitor for, say, a neurodegenerative condition, could you inadvertently make them more vulnerable to infections by viruses that normally rely on necroptosis to be detected and eliminated? The question hasn’t been answered definitively in humans, and short-duration safety trials in healthy volunteers can’t capture this kind of immunological nuance. It’s the sort of long-term risk that will only become clear as larger and longer trials in patients move forward.
How the RIPK1-RIPK3 Structure Shapes Drug Design
At a molecular level, the interaction between RIPK1 and RIPK3 that forms the necrosome involves an unusual structural feature. The two proteins use short motifs called RHIMs (RIP homotypic interaction motifs) to bind together and build an amyloid-like fibrillar structure. High-resolution structural work has revealed that this complex forms what researchers describe as a serpentine fold, with alternating short strands and turns from both proteins interlocked into a hydrophobic core stabilized by stacking interactions.20Cell. The Structure of a RIPK1-RIPK3 Hetero-Amyloid Signaling Complex
Understanding this structure has practical consequences for inhibitor design. Most current RIPK1 inhibitors work by binding to RIPK1’s kinase domain, either at its allosteric site or its ATP pocket, and locking it in an inactive shape. But knowing the detailed structure of the necrosome opens up the possibility of disrupting the RIPK1-RIPK3 interaction itself, potentially offering an alternative way to block the cascade. Researchers have also used structural insights from one target to improve drugs aimed at another. One group recently reported developing potent new RIPK1 inhibitors by starting from the structure of a known RIPK3 inhibitor and re-engineering it to bind RIPK1 selectively. The lead compound that emerged from this approach was effective when given orally in mouse models of both acute and chronic inflammatory diseases.5PubMed. Structure-based development of potent and selective type-II kinase inhibitors of RIPK1 As structural data improves and computational drug design tools become more powerful, the expectation is that the next generation of necroptosis inhibitors will be more selective, more potent, and less likely to hit off-target proteins that cause toxicity problems like those that sank SAR443060.